Du är här

2015-10-01

Apricus Biosciences, Inc.: Apricus Biosciences and Ferring Pharmaceuticals Sign Exclusive Distribution Agreement to Market Topical Erectile Dysfunction Cream V

Apricus Eligible to Receive Up to $18.25 Million in Upfront and Milestone
Payments, in Addition to Royalties on Net Sales

SAN DIEGO, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in
urology and rheumatology, today announced that it has signed an exclusive
distribution agreement with Ferring Pharmaceuticals ("Ferring") to market
Vitaros(TM)(alprostadil), its topical on-demand product for the treatment of
erectile dysfunction ("ED"), in Latin American countries (the "Territory").

Under the terms of the agreement, Apricus will receive $2.25 million from
Ferring in an upfront payment. Apricus is also eligible to receive up to $16
million in regulatory and sales milestone payments, in addition to royalties
based on Ferring's net sales of the product in the Territory. In exchange,
Ferring will have the exclusive right to commercialize Vitaros in the
Territory, which covers Latin America, including certain Caribbean countries.
Ferring will be responsible for obtaining all necessary regulatory approvals.

"We look forward to our collaboration with Ferring as they expand the regions
in which Vitaros, the first and only topical on-demand treatment for erectile
dysfunction, is available," said Richard Pascoe, Chief Executive Officer of
Apricus. "We are pleased that we have been able to license Vitaros in yet
another important market outside of Europe as we seek to make Vitaros
available to men with erectile dysfunction throughout the world who have yet
to be treated satisfactorily."

"We are excited by the opportunity to work with Apricus to commercialize
Vitaros, an innovative product that complements Ferring's existing
portfolio," said Michel Pettigrew, President of the Executive Board and Chief
Operating Officer at Ferring. "Vitaros will provide an alternative treatment
for men suffering from erectile dysfunction in Latin America, while also
allowing us to strengthen our presence in the region."

Vitaros is a new potential entrant into the ED treatment market, offering a
range of benefits that make it appealing to a large number of patients.
Vitaros is a topical ED cream that delivers rapid onset (generally 5-15
minutes), treatment duration of approximately one hour and a favorable safety
profile. Vitaros' local delivery provides an attractive alternative for many
patients, but particularly those with complications that preclude them from
using the orally delivered systemic treatments or who prefer to avoid the
injectable forms of alprostadil.

According to IMS Health, the global ED market in 2014 was in excess of $6.7
billion annually. Outside of the United States, Vitaros has the potential to
generate for Apricus over $200 million in future milestone payments, as well
as potential royalty revenue on net product sales. Moreover, Apricus intends
to leverage Vitaros through additional licensing efforts in key markets in
Asia.

About Ferring Pharmaceuticals

Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a
research-driven, specialty biopharmaceutical group active in global markets.
The company identifies, develops and markets innovative products in the areas
of reproductive health, urology, gastroenterology, endocrinology and
orthopedics. Ferring has its own operating subsidiaries in nearly 60
countries and markets its products in 110 countries.

For further information on Ferring or its products, visitwww.ferring.com.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus has initiated a
Phase 2b trial for fispemifene, a selective estrogen receptor modulator for
the treatment of symptomatic male secondary hypogonadism, and plans to
conduct additional studies in other urological conditions. Apricus has
completed a Phase 2a trial for RayVa(TM), its product candidate for the
treatment of the circulatory disorder Raynaud's phenomenon, and plans to
conduct additional clinical trials in patients with Raynaud's phenomenon
secondary to scleroderma. Apricus' lead commercial product, Vitaros®/(TM),
for the treatment of erectile dysfunction, is approved in Europe and Canada
and is being commercialized in several countries in Europe. Apricus recently
in-licensed the U.S. development and commercialization rights for Vitaros
from Allergan. Apricus' European marketing partners for Vitaros include
Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda
Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.)
and Ferring International Center S.A. (Ferring Pharmaceuticals). Apricus'
second-generation room temperature Vitaros is currently under development.

For further information on Apricus, visithttp://www.apricusbio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act, as amended. Statements in this
press release that are not purely historical are forward-looking statements.
Such forward-looking statements include, among other things: references to
the potential for the product to achieve commercial success generally or in
any specific territory and for Apricus to receive future milestone and
royalty revenue; Apricus' intention to expand licensing efforts in additional
markets, such as Asia; and the size of the commercial opportunity for the
product, particularly in the Territory. Actual results could differ from
those projected in any forward-looking statements due to a variety of reasons
that are outside of Apricus' control, including, but not limited to: Apricus'
dependence on its commercial partners to carry out the commercial launch or
grow sales of Vitaros in various territories, such as Ferring in the
Territory, Majorelle in France, Bracco in Italy, Sandoz in Germany, Sweden
and Belgium, Takeda in the United Kingdom and Recordati in Spain; competition
in the ED market and other markets in which Apricus and its partners operate;
the effect of the previously-reported out-of-stock situation for Vitaros in
Germany and the potential that Apricus' partner there, Sandoz, does not
resume ordering product for Germany or other countries pending the results of
an ongoing out-of-specification investigation by our contract manufacturer;
Apricus' ability to obtain and maintain intellectual property protection for
the product; its ability to further develop its product Vitaros for the
treatment of ED, such as the room temperature version of Vitaros; Apricus'
ability to raise additional funding that it may need to continue to pursue
its commercial and business development plans; the fluctuation of currency
exchange rates; the potential for adverse reactions to the product; its
ability to negotiate and enter into acceptable terms for new licensing
agreements; and market conditions. These forward-looking statements are made
as of the date of this press release, and Apricus assumes no obligation to
update the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward- looking statements.
Readers are urged to read the risk factors set forth in Apricus' most recent
annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q,
and other filings made with the SEC. Copies of these reports are available
from the SEC's website atwww.sec.govor without charge from Apricus.

CONTACT: Matthew Beck
mbeck@troutgroup.com
The Trout Group LLC

(646) 378-2933
---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire

HUG#1956028

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.